Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors

被引：43

作者：

Santra, Sampa

Sun, Yue

Korioth-Schmitz, Birgit

Fitzgerald, Julie ^{[2
]}

Charbonneau, Cherie

Santos, Giannina

Seaman, Michael S.

Ratcliffe, Sarah J. ^{[2
]}

Monteflori, David C. ^{[3
]}

Nabel, Gary J. ^{[4
]}

Ertl, Hildegund C. J. ^{[2
]}

Letvin, Norman L. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis,Dept Med, Boston, MA 02215 USA

[2] Univ Penn, Sch Med, Wistar Inst, Philadelphia, PA 19104 USA

[3] Duke Univ, Med Ctr, Dept Surg, Lab AIDS Vaccine Res & Dev, Durham, NC 27710 USA

[4] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA

来源：

VACCINE | 2009年 / 27卷 / 42期

关键词：

Chimpanzee adenovirus; HIV-1; vaccine; IMMUNODEFICIENCY-VIRUS TYPE-1; IMMUNE-RESPONSES; NEUTRALIZING ANTIBODIES; VACCINE CARRIERS; NONHUMAN-PRIMATES; SIV CHALLENGE; HIV-1; VACCINE; VIREMIA; STEP; IMMUNOGENICITY;

D O I：

10.1016/j.vaccine.2009.07.050

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Pre-existing immunity to human adenovirus serotype 5 (AdHu5) has been shown to suppress the immunogenicity of recombinant Ad5 (rAdHu5) vector-based vaccines for human immunodeficiency virus type 1 (HIV-1) in both preclinical studies and clinical trials. As a potential solution to this problem we developed adenovirus vaccine vectors of chimpanzee origin. In the present study we assessed the immunogenicity of various chimpanzee adenovirus vectors in a prime/boost regimen to HIV-1 envelope and SIV Gag-Pol in rhesus monkeys and their ability to protect against pathogenic viral challenge. Although rAdHu5-primed monkeys had higher magnitude T cell responses than rAdC7 or rAdC68 prior to challenge, the rAdC7-rAdC1/C5 and rAdHu5-rAdC1/C5 immunizations resulted in comparable magnitude recall cellular immune responses and comparable level of control of viremia post-challenge. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：5837 / 5845

页数：9

共 34 条

[1] Adenovirus vector-based vaccines for human immunodeficiency virus type 1 [J].

Barouch, DH ;

Nabel, GJ .

HUMAN GENE THERAPY, 2005, 16 (02) :149-156

[2] Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].

Barouch, DH ;

Pau, MG ;

Custers, JHHV ;

Koudstaal, W ;

Kostense, S ;

Havenga, MJE ;

Truitt, DM ;

Sumida, SM ;

Kishko, MG ;

Arthur, JC ;

Korioth-Schmitz, B ;

Newberg, MH ;

Gorgone, DA ;

Lifton, MA ;

Panicali, DL ;

Nabel, GJ ;

Letvin, NL ;

Goudsmit, J .

JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297

[3] Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].

Barouch, DH ;

Santra, S ;

Schmitz, JE ;

Kuroda, MJ ;

Fu, TM ;

Wagner, W ;

Bilska, M ;

Craiu, A ;

Zheng, XX ;

Krivulka, GR ;

Beaudry, K ;

Lifton, MA ;

Nickerson, CE ;

Trigona, WL ;

Punt, K ;

Freed, DC ;

Guan, LM ;

Dubey, S ;

Casimiro, D ;

Simon, A ;

Davies, ME ;

Chastain, M ;

Strom, TB ;

Gelman, RS ;

Montefiori, DC ;

Lewis, MG ;

Emini, EA ;

Shiver, JW ;

Letvin, NL .

SCIENCE, 2000, 290 (5491) :486-492

[4] Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination [J].

Barouch, DH ;

Santra, S ;

Kuroda, MJ ;

Schmitz, JE ;

Plishka, R ;

Buckler-White, A ;

Gaitan, AE ;

Zin, R ;

Nam, JH ;

Wyatt, LS ;

Lifton, MA ;

Nickerson, CE ;

Moss, B ;

Montefiori, DC ;

Hirsch, VM ;

Letvin, NL .

JOURNAL OF VIROLOGY, 2001, 75 (11) :5151-5158

[5] Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial [J].

Buchbinder, Susan P. ;

Mehrotra, Devon V. ;

Duerr, Ann ;

Fitzgerald, Daniel W. ;

Mogg, Robin ;

Li, David ;

Gilbert, Peter B. ;

Lama, Javier R. ;

Marmor, Michael ;

del Rio, Carlos ;

McElrath, M. Juliana ;

Casimiro, Danilo R. ;

Gottesdiener, Keith M. ;

Chodakewitz, Jeffrey A. ;

Corey, Lawrence ;

Robertson, Michael N. .

LANCET, 2008, 372 (9653) :1881-1893

[6] Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor [J].

Cohen, CJ ;

Xiang, ZQ ;

Gao, GP ;

Ertl, HCJ ;

Wilson, JM ;

Bergelson, JM .

JOURNAL OF GENERAL VIROLOGY, 2002, 83 :151-155

[7] A simian replication-defective vaccine to HIV-1 gag [J].

Fitzgerald, JC ;

Gao, GP ;

Reyes-Sandoval, A ;

Pavlakis, GN ;

Xiang, ZQ ;

Wlazlo, AP ;

Giles-Davis, W ;

Wilson, JM ;

Ertl, HCJ .

JOURNAL OF IMMUNOLOGY, 2003, 170 (03) :1416-1422

[8] Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector [J].

Kostense, S ;

Koudstaal, N ;

Sprangers, M ;

Weverling, GJ ;

Penders, G ;

Helmus, N ;

Vogels, R ;

Bakker, M ;

Berkhout, B ;

Havenga, M ;

Goudsmit, J .

AIDS, 2004, 18 (08) :1213-1216

[9] Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys [J].

Liu, Jinyan ;

Ewald, Bonnie A. ;

Lynch, Diana M. ;

Denholtz, Matthew ;

Abbink, Peter ;

Lemckert, Angelique A. C. ;

Carville, Angela ;

Mansfield, Keith G. ;

Havenga, Menzo J. ;

Goudsmit, Jaap ;

Barouch, Dan H. .

JOURNAL OF VIROLOGY, 2008, 82 (10) :4844-4852

[10] Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys [J].

Liu, Jinyan ;

O'Brien, Kara L. ;

Lynch, Diana M. ;

Simmons, Nathaniel L. ;

La Porte, Annalena ;

Riggs, Ambryice M. ;

Abbink, Peter ;

Coffey, Rory T. ;

Grandpre, Lauren E. ;

Seaman, Michael S. ;

Landucci, Gary ;

Forthal, Donald N. ;

Montefiori, David C. ;

Carville, Angela ;

Mansfield, Keith G. ;

Havenga, Menzo J. ;

Pau, Maria G. ;

Goudsmit, Jaap ;

Barouch, Dan H. .

NATURE, 2009, 457 (7225) :87-91

← 1 2 3 4 →